MARKET

NXTC

NXTC

Nextcure
NASDAQ
4.380
+0.200
+4.78%
Opening 14:53 07/24 EDT
OPEN
4.200
PREV CLOSE
4.180
HIGH
4.530
LOW
4.020
VOLUME
167.66K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
1.550
MARKET CAP
17.82M
P/E (TTM)
-0.2336
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NXTC last week (0713-0717)?
Weekly Report · 4d ago
NextCure trading resumes
TipRanks · 07/16 14:45
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/15 12:05
Analyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC
TipRanks · 07/15 10:15
Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/15 08:32
NextCure Announces Transformative All-Stock Merger With Avere
TipRanks · 07/15 08:10
Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict
NASDAQ · 07/15 03:18
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/14 21:05
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.